Dr Shaun Fleming

Learn more about Monash Health’s Haematology team.

Dr Shaun Fleming

Shaun Fleming is a haematologist and bone marrow transplant physician with co-appointments at Monash Health and Alfred Health. Shaun has a particular interest in allogeneic stem cell transplantation (alloHSCT) and in acute leukaemia. He is the lead investigator on studies in acute lymphoblastic leukaemia (ALL) including the recently completed ALL08 study which evaluated the usage of novel immunotherapies in the management of older adults with B-ALL and leads the MrDRIVE study to investigate MRD directed therapy in older adults with B-ALL.

Shaun is co-chair of the Optimal Care Pathways initiative in ALL and is a member of the Australasian Leukaemia and Lymphoma Group (ALLG), ALL working party. His research interests include immunotherapies in ALL including chimeric antigen receptor T-cells (CART), novel therapies in ALL, allogeneic stem cell transplant risk stratification, measurable residual disease assessment and the application of machine learning to haematology practice.

Through his position at Monash Health, Shaun helps facilitate access for Monash patients to allogeneic stem cell transplantation ensuring their early assessment, risk stratification and management through the transplant process, and facilitating their ongoing care at Monash Health following the completion of their allogeneic stem cell transplant.

Top 5 publications within the last 5 years

Fleming S, Ong DM, Jackson K, Avery S, Mollee P, Marlton P, Kennedy G, Wei A, Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia. Br J Haematol 2017, (2), 2017, p. 328, 10.1111/bjh.1406. Lead CI on this body of work

Marquis M, Beaubois C, Lavallee VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting S, Fleming S, Schwarer A, Grimwade D, Grey W, Hills R, Vyas P, Russell N, Sauvageu G, Herbet J, High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia, Blood Cancer Journal, 2018, 8:68, p1-12, DOI:10.1038/s41408-018-0103-6 Significant contributions to this body of work.

Tan P, Tiong IS, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, Spencer A, Wei A, The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study, Oncotarget 2017. Significant contributions to this body of work, by way of clinical input and correlative links.

Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W, Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, Cancer Discovery 2021 Significant contribution to this body of work during initial concept discussion, patient recruitment as an investigator, manuscript writing and review

Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM, MacRaild S, Ivey A, Tiong I, Fleming S, Brown FC, Loo S, Majewski IJ, Bohlander SK, Wei AH, Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase ib dose-escalation study of venetoclax combined with modified intensive chemotherapy, Journal of Clinical Oncology, 2020 38(30)pp3507-3517 Significant contribution in patient recruitment as an investigator, manuscript writing and review, data analysis

Our Emergency Departments are experiencing extreme demand. If your condition is urgent but not a medical emergency, please consider alternative care options.Learn more
+